FDA
-
-
-
-
-
-
-
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by
-
-
-
-
-
-
-
Celularity (CELU) Submits FDA Request for Orphan Drug Designation for PDA-002
-
-
-
-
-
-
-
Correcting & Replacing -- Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (CTW) to be Regulated as a Device Wi
-
-
-
-
-
-
-
Celularity (CELU) Appoints Adrian Kilcoyne as Chief Medical Officer
-
-
-
-
-
-
-
Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML
-
-
-
-
-
322,101 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

